Erratum: Graft failure in the modern era of allogeneic hematopoietic SCT

Olsson, Richard F.; Remberger, Mats; Schaffer, Marie; Berggren, Daniel Moreno; Bm, Svahn; Mattsson, Jonas; Ringdén, Olle

doi:10.1038/bmt.2013.32

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary rejection (failure to achieve an absolute neutrophil count of !0.5 Â 10 9 /L for three consecutive days or donor chimerism of <5%) was observed in eight patients (7%). Acknowledging that some patient also received RIC in this study, 7% is still quite high compared with the current literature (retrospective studies have estimated the overall incidence of graft failure around 5.5%) [24][25][26] . The 4-year OS of children with AML who received transplants between 2008 and 2012 was slightly more than 40%.…”

Section: Discussionmentioning

confidence: 65%

Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study

et al. 2020

View full text Add to dashboard Cite

The survival rates of children with high-risk acute myeloid leukemia (AML) treated with hematopoietic stem cell transplant (HSCT) range from 60% to 70% in high-income countries. The corresponding rate for Brazilian children with AML who undergo HSCT is unknown. We conducted a retrospective analysis of 114 children with AML who underwent HSCT between 2008 and 2012 at institutions participating in the Brazilian Pediatric Bone Marrow Transplant Working Group. At transplant, 38% of the children were in first complete remission (CR1), 37% were in CR2, and 25% were in CR3+ or had persistent disease. The donors included 49 matched-related, 59 matched-unrelated, and six haploidentical donors. The most frequent source of cells was bone marrow (69%), followed by the umbilical cord (19%) and peripheral blood (12%). The 4-year overall survival was 47% (95% confidence interval [CI] 30%–57%), and the 4-year progression-free survival was 40% (95% CI 30%–49%). Relapse occurred in 49 patients, at a median of 122 days after HSCT. There were 65 deaths: 40 related to AML, 19 to infection, and six to graft versus host disease. In conclusion, our study suggests that HSCT outcomes for children with AML in CR1 or CR2 are acceptable and that this should be considered in the overall treatment planning for children with AML in Brazil. Therapeutic standardization through the adoption of multicentric protocols and appropriate supportive care treatment will have a significant impact on the results of HSCT for AML in Brazil and possibly in other countries with limited resources.

show abstract

Section: Discussionmentioning

confidence: 65%

Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Yet, even with HSC transplantation, there is still opportunity for significant improvements in efficacy that would occur with a means to determine HSC-specific dose. A prime example is umbilical cord blood HSC transplantation therapies, for which units fail at a high rate (18-24%), because of insufficient stem cells [34]. Without being able to count HSCs, it has been impossible to know which cord blood units would have insufficient potency.…”

Section: Discussionmentioning

confidence: 99%

A Computational Simulation Technology for Specific Counting of Perinatal and Postnatal Human Tissue Stem Cells for Transplantation Medicine

Dutton¹,

Abdi²,

Minnetyan³

et al. 2020

Transplantation

View full text Add to dashboard Cite

Although tissue stem cells are essential for the maintenance, renewal, and repair of vertebrate organs and tissues, previously, the simple act of counting them has not been possible. For more than a half-century, progress in tissue stem cell research and medicine has been undermined by the lack of a means to determine tissue stem cell number. In particular, a major unmet need for stem cell transplantation medicine has been a way to quantify the specific dosage of tissue stem cell treatments. The counting problem persists because no biomarkers are known that identify tissue stem cells specifically, without also counting their more abundant committed progenitor progeny cells. Here, we describe integration of principles of tissue stem cell asymmetric self-renewal kinetics with computational simulation to achieve specific and accurate counting of therapeutic tissue

show abstract

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation

Aydin

Dellacasa²,

Manetta³

et al. 2020

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Background: Patients with post-transplant cytopenias due to poor graft function or primary engraftment failure show poor prognosis with a high mortality rate mainly because of graft versus host disease (GVHD), infection and/or bleeding. Treatment options are scarce and a CD34+ stem cell boost or a second bone marrow transplantation may be required to restore adequate haematopoiesis. Methods: In the present study patients with primary engraftment failure ( n = 1) and refractory poor graft function ( n = 11) were treated with eltrombopag in a single centre. The reason for eltrombopag treatment was trilineage cytopenia in six patients, bilineage cytopenia in three patients and single lineage cytopenia in three patients. Eltrombopag was initiated at a median of 214 (range: 120–877) days after haematopoietic stem cell transplantation (HCST) and administered for a median time of 114 (range: 12 days to >490) days. In 8/12 patients eltrombopag was introduced at a dose of 75 mg/day and then increased to 150 mg/day after 1 week; 1 patient was given 50 mg eltrombopag per day, and 3 patients received 75 mg daily. Results: In 10/12 patients eltrombopag significantly enhanced blood count values and patients became transfusion independent. Once stable haematological response was obtained, treatment was tapered until final discontinuation in 9/10 responding patients. No grade 3 or 4 toxicities were observed. At time of last follow up, 3/12 patients were dead, 2 due to disease relapse, 1 due to GVHD and pneumonia. All patients except one maintained their complete response and remain transfusion independent at a median of 858 (range: 429–1119) days. Conclusion: These preliminary data confirm that eltrombopag is able to rescue multilineage haematopoiesis in patients with treatment-refractory cytopenias after allogeneic HSCT.

show abstract

Erratum: Graft failure in the modern era of allogeneic hematopoietic SCT

Cited by 4 publications

References 0 publications

Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study

Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study

A Computational Simulation Technology for Specific Counting of Perinatal and Postnatal Human Tissue Stem Cells for Transplantation Medicine

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation

Contact Info

Product

Resources

About